Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 4 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 2Tumor-Agnostic 1Other solid neoplasm 1Lymphoid 1Gastrointestinal 1CNS 1

Conditions

Colorectal Neoplasms 1

Interventions

Gemcitabine 153Oxaliplatin 124Fluorouracil 108Capecitabine 105pembrolizumab 92Bevacizumab 79Leucovorin 76Irinotecan 72Nivolumab 70130-nm albumin-bound paclitaxel 68Paclitaxel 62Cisplatin 62Cetuximab 60Cyclophosphamide 47Albumin-Bound Paclitaxel 45Radiotherapy 39Docetaxel 36durvalumab 33Sorafenib 32Taxes 29Carboplatin 27fludarabine 26tislelizumab 25Drug Therapy 25atezolizumab 23Folfox protocol 23regorafenib 20lenvatinib 19Ipilimumab 19sintilimab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Antibodies, Monoclonal × Gastrointestinal × Clear all
NCT02713373 2022-10-06

Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery

Roswell Park Cancer Institute

Phase 1/2 Completed
45 enrolled 14 charts
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡